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A B S T R A C T

Background: Alzheimer’s disease (AD) is generally thought to spare primary sensory function; however, such
interpretations have drawn from a literature that has rarely taken into account the variable cognitive
declines seen in patients with AD. As these cognitive domains are now known to modulate cortical somatosensory processing, it remains possible that abnormalities in somatosensory function in patients with AD
have been suppressed by neuropsychological variability in previous research.
Methods: In this study, we combine magnetoencephalographic (MEG) brain imaging during a paired-pulse
somatosensory gating task with an extensive battery of neuropsychological tests to investigate the inﬂuence
of cognitive variability on estimated differences in somatosensory function between biomarker-conﬁrmed
patients on the AD spectrum and cognitively-normal older adults.
Findings: We show that patients on the AD spectrum exhibit largely non-signiﬁcant differences in somatosensory function when cognitive variability is not considered (p-value range: .020 .842). However, once
attention and processing speed abilities are considered, robust differences in gamma-frequency somatosensory response amplitude (p < .001) and gating (p = .004) emerge, accompanied by signiﬁcant statistical suppression effects.
Interpretation: These ﬁndings suggest that patients with AD exhibit insults to functional somatosensory processing in primary sensory cortices, but these effects are masked by variability in cognitive decline across
individuals.
Funding: National Institutes of Health, USA; Fremont Area Alzheimer’s Fund, USA
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)

1. Introduction
The pathological trajectory of Alzheimer’s disease (AD) is now
thought to begin as early as 20 years prior to the manifestation of
hallmark declines in memory and other cognitive functions, beginning with the accumulation of amyloid-b “plaques” and ﬁbrillary
“tangles” rich in hyperphosphorylated tau [1,2]. Accompanying these
early proteinopathies are measurable changes in the patterns of functional neuronal activity and structural neuronal morphology and
integrity [1 3]. One of the most widely replicated ﬁndings in the AD
* Corresponding author at: McConnell Brain Imaging Centre, Montreal Neurological
Institute, McGill University, 845 Sherbrooke St W, Montreal, QC H3A 0G4, Canada.
E-mail address: alexander.wiesman@mail.mcgill.ca (A.I. Wiesman).

neuroimaging literature is the sparing of primary sensory cortices,
and particularly the primary sensorimotor cortices, until relatively
late in the disease course [4 7]. In addition, although the functional
gating of redundant auditory information has been shown to be aberrant in patients with AD [8 11], no such differences have been
reported in the somatosensory domain. In combination with a sparsity of studies reporting neural somatosensory deﬁcits in patients
with AD [12], as well as others reporting null effects [7], this has led
to a general consensus that somato-motor function is spared by the
disease.
However, the functional neuroimaging literature has not considered a major confounding variable that is now known to robustly and
systematically inﬂuence the functional processing of somatosensory
stimuli: higher-order cognitive function. Patients with AD are known

https://doi.org/10.1016/j.ebiom.2021.103638
2352-3964/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
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Research in context
Evidence before this study
Extant literature from brain structure imaging and post-mortem neuropathology suggests that somatosensory neural systems (i.e., the brain systems supporting the sense of touch) are
relatively unaffected by Alzheimer’s disease (AD), along with
other primary sensory systems. However, recent research has
established a dynamic interplay between somatosensory neural
systems and the brain systems supporting attention and executive functions. Patients with AD often have impaired attention
and executive functions, but these impairments are highly variable across individuals, and so it is possible that controlling for
variability in these cognitive abilities would reveal differences
in somatosensory processing in these patients.
Added value of this study
This study investigates the usefulness of controlling for cognitive variability while testing for differences in somatosensory
neural functions in patients with AD. The primary ﬁnding is
that variability in attention (i.e., the ability to selectively focus
cognitive resources) and processing speed (i.e., the time it takes
to understand and react to incoming sensory information) abilities masks the detection of changes in somatosensory neural
functions in patients with AD.
Implications of all the available evidence
These ﬁndings suggest that variability in cognitive declines, and
in particular attention and processing speed, should be taken
into account when testing for primary sensory impairments in
patients with AD. Additionally, they suggest that when cognitive variability is properly controlled for, patients with AD
exhibit robust changes in the neural processing of incoming
somatosensory information.

to exhibit variable declines in attention and processing speed [13,14],
indicating that differing components of cognitive control are deﬁcient
at an early disease stage. These same cognitive functions are now
known to interact with the neural processing of somatosensory stimuli [15 22], as well as the functional gating of redundant somatosensory [23] and auditory [24 27] information. Thus, it seems possible
that unaccounted-for variability in attention and processing speed
function might be masking functional aberrations in somatosensory
processing in patients with AD. Supporting this possibility, previous
ﬁndings of aberrant auditory processing in AD have been found to
relate systematically to similar cognitive dysfunctions [10]. Further, a
number of studies using animal models of AD, which do not exhibit
the same degree of specialization and variability in executive functions as humans, have reported profound somatosensory aberrations
[28,29].
In this study, we combine source imaged magnetoencephalography (MEG) during a paired-pulse somatosensory gating paradigm
with an extensive series of neuropsychological assessments to determine whether variability in cognitive function masks somatosensory
deﬁcits in patients on the AD spectrum. MEG data were examined in
the time and time-frequency domains at the sensor-level, and signiﬁcant neural responses were source imaged. The relative response
amplitude to somatosensory stimulation, as well as the gating of this
sensory information between stimulation pairs was examined.
We hypothesized that attention and processing speed abilities, in
particular, would play key roles in modelling differences in functional
somatosensory activity between patients on the AD spectrum and a

matched group of cognitively-normal older adults, while other cognitive faculties including memory, learning, and verbal function, would
not.
2. Methods
2.1. Participants and ethics
The Institutional Review Board at the University of Nebraska Medical Center reviewed and approved this investigation (protocol #30218-FB), and all research protocols complied with the Declaration of
Helsinki. Written informed consent was obtained from each participant and, for participants in the AD spectrum group, from their
spouse/child informant following a detailed description of the study.
For individuals with diminished capacity to make an informed decision regarding research participation, educated assent was acquired
from the participant, in addition to informed consent of their legally
authorized representative. All participants completed the same
experimental protocol. Exclusionary criteria for both groups included
any medical illness affecting central nervous system function, any
neurological disorder (other than Alzheimer’s disease), history of
head trauma, moderate or severe depression (Geriatric Depression
Scale  10; [30]), and current substance abuse.
2.2. Alzheimer’s disease spectrum group
Forty-four participants between 50 and 80 years of age, and without a history of psychiatric or other neurological disease (i.e., aside
from amnestic mild cognitive impairment [MCI] or AD), were
screened for recruitment into the AD spectrum group. These participants were initially referred to the study from the Memory Disorders
Clinic at the University of Nebraska Medical Center (Omaha, NE, USA)
and/or the Geriatric Medicine Clinic at Nebraska Medicine (Omaha,
NE, USA) where they were being treated for amnestic memory complaints. Prior to being screened for this study all such participants
were determined as having either aMCI or mild probable AD by a fellowship-trained neurologist using standard clinical criteria [31]. In
addition to one of these diagnoses, a positive biomarker (using
whole-brain quantitative amyloid-beta [Ab] positron emission
tomography [PET]) was also required for inclusion into the ﬁnal AD
spectrum participant sample. One participant was excluded from this
group due to a major incidental ﬁnding that was likely to impact cognitive function, and another disenrolled due to COVID-19 related
health concerns. Four additional participants were excluded after
they were indicated as being amyloid-beta (Ab) negative by means of
whole-brain Ab PET scanning with ﬂorbetapir 18F (see Florbetapir 18F
PET below). After exclusions, 38 Ab-positive participants remained
for inclusion into the AD spectrum group.
2.3. Healthy aging comparison group
For comparison of the AD spectrum patients to a group of cognitively normal older adults, 20 additional participants who reported
no subjective cognitive concerns were screened for inclusion into the
study. Nineteen of these participants had received a biomarker test
for Ab-positivity within the past ﬁve years, and were conﬁrmed biomarker-negative, while one participant received no such test, but
performed exceedingly well on all neuropsychological examinations.
Of note, the 19 amyloid-negative participants were recruited based
on their previous enrollment in an unrelated clinical trial of an antiamyloid drug in cognitively healthy older adults, where they were
discovered to be amyloid-negative during the screening process and
excluded from participation. These participants did not report cognitive disturbances, which was conﬁrmed by our own detailed neuropsychological assessments (see Methods: Neuropsychological Testing
and Table 1), and were not being seen at either of the clinics
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Table 1
Demographics and neuropsychological proﬁles.

CN
ADS
p
CN
ADS
p

Age (years)

Sex (% female)

Handedness (% left)

72.17 (4.66)
69.21 (6.91)
.106
MoCA*
27.23 (1.92)
19.13 (4.76)
<.001

55.56
47.37
.454
MMSE
29.17 (1.10)
23.66 (4.15)
<.001

5.56
7.89
.751
Learning
0.54 (0.75)
2.04 (0.88)
<.001

Education (years)

16.33 (2.89)
15.50 (2.72)
.345
Memory
Attention
0.28 (0.56)
0.52 (0.61)
2.28 (0.70)
0.77 (1.06)
<.001
<.001

Verbal Fluency
0.14 (0.78)
1.04 (1.01)
<.001

Processing Speed
0.72 (0.83)
0.90 (1.42)
<.001

Values reported are mean (SD), with p-values indicating signiﬁcance of an unpaired t-test (continuous variables) or chi-square test
(categorical variables). CN: cognitively normal; ADS: Alzheimer’s disease spectrum; MoCA: Montreal Cognitive Assessment; MMSE:
Mini-Mental State Exam.
* n = 51 (MoCA scores were missing in ﬁve CN participants due to a data collection error).

referenced above. Cognitively-normal participants were screened for
inclusion in our study alongside the enrollment of the AD spectrum
participants, and those who most closely matched the demographic
makeup of the patient group were contacted. One participant was
excluded from the comparison group for not completing the somatosensory experiment in its entirety, and one other for excessively
noisy data (i.e., large movement/magnetic artifacts). After exclusions,
18 participants remained for inclusion into the cognitively-normal
group.
Demographics for each group, as well as comparisons between
groups, can be found in Table 1. Essential demographic factors were
matched across the groups.
2.4. Florbetapir 18F PET acquisition and analysis
Combined PET/computed tomography (CT) data using 18F-ﬂorbetapir (AmyvidTM , Eli Lilly) were collected following procedures
described by the Society of Nuclear Medicine and Molecular Imaging
(3D acquisition; single intravenous slow-bolus < 10 mL; dose = 370
MBq; waiting period = 30 50 min; acquisition = 10 min; [32]). A GE
Discovery MI digital PET/CT scanner (Waukesha, WI) was used to
acquire whole-brain quantitative images of amyloid-beta uptake.
Images were attenuation-corrected using the CT data, and reconstructed in MIMNeuro (slice thickness = 2 mm; 33), converted to
voxel-wise standardized uptake values (SUV) based on body weight,
and then normalized into Montreal Neurological Institute (MNI)
space. At this stage, each scan was read by a fellowship-trained neuroradiologist, who was blinded to their group assignment, and
assessed as being “amyloid-positive” or “amyloid-negative” using
established clinical criteria [33]. Patients who were amyloid-negative
were excluded from the AD spectrum group. Images were then normalized to the crus of the cerebellum using the spatially unbiased
infra-tentorial (SUIT) template [34] to generate voxel-wise maps of
SUV ratios (SUVR; 2). Voxel-wise amyloid SUVRs were then extracted
using peak somatosensory response coordinates from the grandaveraged gamma-frequency MEG responses (i.e., across both stimulations and all participants) and converted into MNI space using a nonlinear transform [35]. These SUVR data were used to test hypothesized relationships with cognition and somatosensory function.
2.5. Neuropsychological testing
After screening and informed consent, participants completed a
battery of neuropsychological assessments, with raw scores for each
participant being converted to demographically-adjusted z-scores
(e.g., based on age, education, etc.) using published normative data
[36 39]. This battery was developed in collaboration with a clinical
neuropsychologist specializing in memory disorders, and focused on
ﬁve cognitive domains generally impacted in patients with AD: verbal
memory (Wechsler Memory Scale [WMS-IV] Logical Memory II
Delayed Recall and Recognition [40]; Hopkins Verbal Learning Test-

Revised [HVLT-R] Delayed Recall and Recognition Discriminability
Index [39]), learning (WMS-IV Logical Memory I Recall [40]; HVLT-R
Learning Trials 1-3 [39]), attention and executive function (Wechsler
Adult Intelligence Scale [WAIS-IV] Digit Span Forward, Backward,
and Sequencing [38]; Trail Making Test Part B [37]), language (Boston
Naming Test [37]; Controlled Oral Word Association Test/Phonemic
Verbal Fluency [37]; Animals/Semantic Verbal Fluency [37]), and
processing speed (WAIS-IV Coding [38]; Trail Making Test Part A [37]).
Demographically corrected z-scores based on test-speciﬁc normative
data were averaged to create composite cognitive domain z-scores
by participant. These domain composite scores were corroborated
within the cognitively-normal group by calculating a ratio of z-scores
representing the average of all correlations amongst intra-domain
tests, divided by the average of all correlations with inter-domain
tests. All domains had a ratio of zintra/zinter > 1.40, and on average zintra/zinter = 2.53 (SD = 1.51), indicating that these domains were »150%
more internally- than externally-related.

2.6. Paired-pulse somatosensory paradigm
During the experiment, participants were seated with their eyes
closed in a custom-made nonmagnetic chair with their head positioned within the MEG helmet-shaped sensor array. Unilateral electrical stimulation was applied to the right median nerve using
external cutaneous stimulators connected to a Digitimer DS7A constant-current stimulator system (HW Medical Products, Neuberg,
Germany). For each participant, at least 80 paired-pulse trials were
collected using an inter-stimulus interval of 500 ms and an inter-pair
interval that randomly varied between 4.3 and 4.8 s. Each pulse was
comprised of a 0.2 ms constant-current square wave that was set to
10% above the motor threshold required to elicit a subtle twitch of
the thumb.

2.7. MEG data acquisition
Our MEG data acquisition, structural coregistration, preprocessing, and sensor-/source-level analyses closely followed the analysis
pipeline of previous manuscripts [23,41 45]. All recordings were
conducted in a one-layer magnetically-shielded room with active
shielding engaged. Neuromagnetic responses were sampled continuously at 1 kHz with an acquisition bandwidth of 0.1 330 Hz using a
306-sensor Elekta/MEGIN MEG system (Helsinki, Finland) equipped
with 204 planar gradiometers and 102 magnetometers. Participants
were monitored during data acquisition via real-time audio-video
feeds from inside the shielded room. Each MEG dataset was individually corrected for head motion and subjected to noise reduction using
the signal space separation method with a temporal extension (correlation limit: .950; correlation window duration: 6 s; [46]). Only data
from the gradiometers were used for further analysis.
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2.8. Structural MRI processing and MEG coregistration
Each participant’s head position was monitored continuously
throughout the recording, and the locations of the head position indicator coils were digitized, together with the three ﬁducial points and
scalp surface (Fastrak 3SF0002, Polhemus Navigator Sciences, Colchester, VT, USA). Using these digitized points, each participant’s
MEG data were co-registered with their own structural T1-weighted
magnetic resonance imaging (MRI) data using BESA MRI (Version 2.0)
prior to source-space analysis. Structural MRI data were aligned parallel to the anterior and posterior commissures and transformed into
standardized space. Following source analysis (i.e., beamforming),
each participant’s 4.0 £ 4.0 £ 4.0 mm functional images were also
transformed into standardized space using the transform that was
previously applied to the structural MRI volume and spatially
resampled.

2.9. MEG preprocessing, time-frequency transformation, and sensorlevel statistics
Cardiac and blink artifacts were removed from the data using signal-space projection (SSP), which was subsequently accounted for
during source reconstruction [47]. The continuous magnetic time
series was then ﬁltered between 0.5 200 Hz plus a 60 Hz notch ﬁlter,
and divided into 3700 ms epochs, with the baseline extending from
700 to 300 ms prior to the onset of the ﬁrst somatosensory stimulus. Of note, we shifted our baseline away from the period immediately preceding stimulus onset to avoid potential contamination by
any anticipatory responses. Epochs containing artifacts were rejected
using a ﬁxed threshold method, supplemented with visual inspection. Across all participants, the average amplitude threshold was
1231.77 (SD = 283.87) fT/cm, the average gradient threshold was
222.41 (SD = 131.10) fT/(cm*ms), and an average of 72.04
(SD = 11.53) trials (out of the original 80) were used for further analysis. Importantly, none of our statistical comparisons were compromised by differences in trial number nor artifact thresholds, as none
of these metrics signiﬁcantly differed across groups (Mann-Whitney
U test; trial number: p = .628; amplitude threshold: p = .972; gradient
threshold: p = .108). Note that a Mann-Whitney test was used here to
account for the non-normal distribution of the number of accepted
trials in the cognitively-normal group (Shapiro-Wilk test; p = .032)
and of the gradient thresholds in both groups (Shapiro-Wilk test; AD
spectrum: p = .002; cognitively-normal: p < .001).
To examine the phase-locked stimulus-evoked responses to
somatosensory stimulation, the epochs remaining after artifact-rejection were averaged across trials to generate a mean time series per
sensor, and the speciﬁc time windows used for subsequent source
analysis were determined by statistical analysis of the sensor-level
time series across both groups and the entire array of gradiometers.
The time windows used for the source analysis were determined
through paired-sample cluster-based permutation tests against baseline, with an initial cluster threshold of p < .001 and 10,000 permutations. The temporal windows of time-domain data that were nonexchangeable with baseline according to these permutation analyses
were used to compute source images using standardized low resolution brain electromagnetic tomography (sLORETA; Tikhonov regularization constant: .01% of the leadﬁeld matrix trace; [48]). The resulting
whole-brain maps were 4-dimensional estimates of current density
per voxel, per time sample. These data were normalized to the sum
of the noise covariance and theoretical signal covariance, and thus
the units are arbitrary. Using the two temporal clusters identiﬁed in
the sensor-level analysis (see below), these maps were averaged over
time and across groups. The resulting maps were then averaged
across the two windows to determine the peak voxel of the timedomain neural response to the stimuli across participants. From this

peak, the sLORETA units were extracted to derive estimates of each
time-domain response amplitude per participant.
In order to also examine the role of band-limited neural responses
to somatosensory stimuli, we transformed the post-artifact-rejection
sensor-level epochs into the time-frequency domain using complex
demodulation [49 51]. The time-frequency analysis was performed
with a frequency-step of 2 Hz and a time-step of 25 ms between 4
and 100 Hz, using a 4 Hz lowpass ﬁnite impulse response (FIR) ﬁlter
with a full-width half maximum in the time domain of »115 ms. The
resulting spectral power estimations per sensor were averaged over
trials to generate time-frequency plots of mean spectral density,
which were normalized by the baseline power of each respective bin
((active-baseline)/baseline), calculated as the mean power during the
700 to 300 ms time period. The time-frequency windows used for
the source analysis were again determined by means of a pairedsample cluster-based permutation test against baseline across all participants and the entire frequency range (4 100 Hz), with an initial
cluster threshold of p < .001 and 10,000 permutations.
Time-frequency resolved beamformer source images were computed with the dynamic imaging of coherent sources approach
(DICS; truncated singular value decomposition [SVD] regularization:
values <.0001% of maximum SVD set to zero; 49, [52]). Following
convention, we computed noise-normalized, source power per voxel
in each participant using active (i.e., task) and passive (i.e., baseline)
periods of equal duration and bandwidth. This approach generated
three-dimensional participant-level pseudo-t maps per each timefrequency cluster identiﬁed in the sensor-level analysis. These voxelwise maps of oscillatory neuronal response amplitude were averaged
within groups across the two time windows identiﬁed through the
statistical analysis, corresponding to stimulations 1 and 2, for display
purposes and then grand-averaged across both stimulations and all
participants. The voxel of maximum amplitude was then identiﬁed
from this grand-averaged map, and virtual sensor data were
extracted from this grand-average peak voxel. This signal was
decomposed into time-frequency space, baseline-corrected, and was
then averaged across the time and/or frequency ranges identiﬁed
through the sensor-level analyses for statistical testing and visualization of the neural amplitude envelope.
For each neural response, relative amplitude values for stimulations 1
and 2 were averaged within each participant to represent the average
neural response to somatosensory stimulation, and somatosensory gating ratios were derived using the following formula: SG = (Astim2 + 2)/
(Astim1 + 2), where A is the relative response amplitude and SG is the gating ratio. The addition of a constant to each stimulation amplitude nulled
any spurious effects of near-zero or negative values on the estimation of
the gating ratio (no constant was added to the sLORETA values, which
are always >0). Participants exhibiting outlier average neural response
amplitudes or somatosensory gating ratios, as determined by a ﬁxed
threshold of §2 standard deviations from the mean, were excluded listwise per each neural response from all statistical models involving that
response. Differences between the groups in major demographic factors
remained unchanged after these exclusions.
2.10. Statistical analysis and software
Since group differences in age approached signiﬁcance, all statistical analyses were performed including age as a nuisance covariate.
Per each neural response of interest, general linear models were initially computed to test for group differences in the average somatosensory neural responses and gating ratios. Next, the cognitive
domain composite scores for attention and processing speed (see
Neuropsychological Testing) were added individually into each of
these two models (i.e., one for group differences in response amplitude and another for group differences in gating ratio) as a covariate
of interest, to determine which cognitive domains signiﬁcantly contributed to prediction of the dependent variable. Differences in model
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predictive value (DR2) between the models with and without the
cognitive scores included were also computed. Cognitive domain
composite scores that fulﬁlled the basic requirements of mediation/
suppression [53,54] were tested for indirect effects on the groupwise
differences in somatosensory function using a nonparametric bootstrapping approach with 10,000 simulations [55]. Relationships
between cognition and amyloid-b uptake were probed using general
linear models that regressed neuropsychological domain scores on
SUVRs from the MEG somatosensory peak voxel, above and beyond
the effects of age. All MEG data preprocessing, coregistration, and
sensor- and source-level analyses were performed in the Brain Electrical Source Analysis software suite (BESA Research v7.0 and BESA
MRI v2.0). Cluster-based permutation testing on MEG sensor-array
data was performed in BESA Statistics (v2.0). General linear models
were computed using the stats package in R [56], and indirect effects
were evaluated using the mediation package [55]. Plotting of model
residuals used ggplot2 [57].
2.11. Role of funding source
The funders had no role in the study design, data collection, data
analyses, interpretation, or writing of this report.
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170 ms post-stimulus in the time domain (cluster-based permutation
test; 10,000 permutations; p < .001). Source imaging of these
responses indicated that they all originated from the hand-knob
region of the postcentral gyrus (Figs. 1 and S1 S2), suggesting
somato-motor origin.
3.1. Variability in processing speed abilities masks increased gamma
somatosensory responses in patients on the AD spectrum
A general linear model of group differences in gamma-frequency
somatosensory response amplitude (i.e., averaged over the two stimulations) initially indicated a signiﬁcant, but weak, increase in amplitude in patients on the AD spectrum (F(1,49) = 5.78, p = .020).
Accounting for variability across participants in processing speed
scores signiﬁcantly enhanced the overall model (Fig. 2a,c; DR2 = .16,
p = .003), and signiﬁcantly increased the model sensitivity to group
differences in gamma response amplitude via an indirect effect
(Fig. 2d; causal mediation analysis; average causal mediation effect
[ACME] = .07, p = .004; average direct effect [ADE] = .19, p < .001;
proportion mediated = .62, p = .005). The addition of no other cognitive domain scores, including attention, learning, memory, and verbal
function, signiﬁcantly contributed to model accuracy (general linear
model; all p’s > .05).

3. Results
Robust neural responses to each somatosensory stimulation were
identiﬁed in the time-frequency domain in the theta (4 8 Hz;
25 75 ms post-stimulus), alpha (8 12 Hz; 225 425 ms post-stimulus), beta (16 24 Hz; 100 350 ms post-stimulus), and gamma
(30 80 Hz; 0 75 ms post-stimulus) bands (Figs. 1a and S1; clusterbased permutation test; 10,000 permutations; p < .001). Additionally,
a signiﬁcant somatosensory evoked response extended from 25 to

3.2. Variability in attention and processing speed masks increased
gamma-frequency somatosensory gating in patients on the AD spectrum
Next, a linear model was computed to examine group differences
in the functional gating of gamma-frequency somatosensory
responses. Again, the initial model (i.e., with no consideration for cognitive domain scores) indicated a weak, and this time non-signiﬁcant,
decrease in the somatosensory gating ratio in patients on the AD

Fig. 1. Oscillatory neural responses to paired-pulse somatosensory stimulation. (a) The spectrogram (top) displays time-frequency data from a representative gradiometer
(MEG0233), with time represented (in milliseconds) on the x-axis and frequency represented (in Hz) on the y-axis. The two vertical dotted lines represent the onset of the pairedpulse somatosensory stimulations (at 0 and 500 ms), and the time-frequency windows used as the pre-stimulus baseline and those identiﬁed as the neural responses to somatosensory stimulation in the sensor-level statistical analysis, are outlined by black dotted rectangles. The topographic maps (bottom left) indicate the spatial distribution of the gammafrequency (30 80 Hz) responses to ﬁrst (left; 0 75 ms) and second (right; 500 575 ms) somatosensory stimulations. The color bar in the middle of the ﬁgure displays the amplitude thresholds (in percent change from baseline) used for display of both the spectrogram and the topographic maps. (b) Inlaid brain images indicate the source-imaged data, averaged over both somatosensory responses and within each group (ADS: Alzheimer’s disease spectrum, red; CN: cognitively-normal, blue), with the amplitude thresholds (in pseudo-t
values) used for display shown on the color bar below. The time series represent peak-voxel amplitude envelopes for these gamma responses, per each group, with time (in milliseconds) on the x-axis and response amplitude (in percent change from baseline) on the y-axis. Shaded areas indicate § 1 standard error of the mean. The baseline interval, as well as
the onset of each somatosensory stimulation, are indicated just above the x-axis.
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Fig. 2. Processing speed abilities suppress group differences in somatosensory response amplitude. The scatterplot in (a) indicates the relationship between processing speed abilities (x-axis) and response amplitude (y-axis), per each group (ADS: Alzheimer’s disease spectrum, red; CN: cognitively-normal, blue), above and beyond the effects of age. The lines
of best ﬁt, per each group, are overlaid with 95% conﬁdence intervals indicated in the shaded area. The scatterplot in (b) indicates the same relationship, above and beyond the
effects of age and group, with the partial correlation coefﬁcient (r) and corresponding p-value overlaid, along with the line of best-ﬁt and 95% conﬁdence intervals. The plot in (c)
represents the difference in response amplitude as a function of group, above and beyond the effects of processing speed and age, with the t-value and corresponding p-value overlaid. Box plots represent conditional means, ﬁrst and third quartiles, and minima and maxima, and violin plots show the probability density. Paths in (d) between the three variables
of interest are represented by blue arrows, with t-values above each indicating the relationship strength, above and beyond the effects of age. The bold t-value at the bottom represents the relationship between group and response amplitude, after accounting for the effect of processing speed scores, and the average causal mediation effect (ACME) at top represents the indirect impact of processing speed on this relationship (10,000 bootstrapping simulations). **p < .005. *p < .05.

spectrum (F(1,49) = 3.96, p = .052). The addition of attention domain
scores to this model signiﬁcantly enhanced both the overall model
(Fig. 3a c; DR2 = .10, p = .020), as well as the sensitivity of the model
to group differences in somatosensory gating (Fig. 3d; causal

mediation analysis; ACME = .01, p = .009; ADE = .02, p = .003; proportion mediated = .67, p = .047). Considering between-participant
variability in processing speed scores also provided enhanced model
accuracy (Fig. 4a c; DR2 = .10, p = .019), and improved prediction of
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Fig. 3. Attention abilities suppress group differences in somatosensory gating. The scatterplot in (a) indicates the relationship between attention abilities (x-axis) and the somatosensory gating ratio (y-axis), per each group (ADS: Alzheimer’s disease spectrum, red; CN: cognitively-normal, blue), above and beyond the effects of age. The lines of best ﬁt, per
each group, are overlaid with 95% conﬁdence intervals indicated in the shaded area. The scatterplot in (b) indicates the same relationship, above and beyond the effects of age and
group, with the partial correlation coefﬁcient (r) and corresponding p-value overlaid, along with the line of best-ﬁt and 95% conﬁdence intervals. The plot in (c) represents the difference in somatosensory gating as a function of group, above and beyond the effects of attention and age, with the t-value and corresponding p-value overlaid. Box plots represent
conditional means, ﬁrst and third quartiles, and minima and maxima, and violin plots show the probability density. Paths in (d) between the three variables of interest are represented by blue arrows, with t-values above each indicating the relationship strength, above and beyond the effects of age. The bold t-value at the bottom represents the relationship
between group and somatosensory gating, after accounting for the effect of attention scores, and the average causal mediation effect (ACME) at the top represents the indirect
impact of attention on this relationship (10,000 bootstrapping simulations). **p < .005. *p < .05.

group differences in somatosensory gating ratios (Fig. 4d, bottom;
causal mediation analysis; ACME = .01, p = .016; ADE = .02, p = .003;
proportion mediated = .59, p = .048). The addition of no other cognitive domain scores, including learning, memory, or verbal function,
signiﬁcantly contributed to model accuracy (all p’s > .05).

No models of the theta, alpha, beta, or evoked responses indicated
a potential suppression of group differences in somatosensory metrics by cognitive scores (Table S1). However, there was a signiﬁcant
difference in the gating of the alpha somatosensory response (F
(1,48) = 4.75, p = .034), such that the gating ratio was reduced in
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Fig. 4. Processing speed abilities suppress group differences in somatosensory gating. The scatterplot in (a) indicates the relationship between processing speed abilities (x-axis)
and the somatosensory gating ratio (y-axis), per each group (ADS: Alzheimer’s disease spectrum, red; CN: cognitively-normal, blue), above and beyond the effects of age. The lines
of best ﬁt, per each group, are overlaid with 95% conﬁdence intervals indicated in the shaded area. The scatterplot in (b) indicates the same relationship, above and beyond the
effects of age and group, with the partial correlation coefﬁcient (r) and corresponding p-value overlaid, along with the line of best-ﬁt and 95% conﬁdence intervals. The plot in (c)
represents the difference in somatosensory gating as a function of group, above and beyond the effects of processing speed and age, with the t-value and corresponding p-value
overlaid. Box plots represent conditional means, ﬁrst and third quartiles, and minima and maxima, and violin plots show the probability density. Paths in (d) between the three variables of interest are represented by blue arrows, with t-values above each indicating the relationship strength, above and beyond the effects of age. The bold t-value at the bottom
represents the relationship between group and somatosensory gating, after accounting for the effect of processing speed scores, and the average causal mediation effect (ACME) at
the top represents the indirect impact of processing speed on this relationship (10,000 bootstrapping simulations). **p < .005. *p < .05.

patients on the AD spectrum. Importantly, since the alpha
response was a decrease from resting levels of synchrony, this
indicates that the gating of this somatosensory response was
reduced in patients compared to their demographically-matched
counterparts.

3.3. Local amyloid-b uptake in primary somatosensory cortex predicts
learning abilities in patients on the AD spectrum
Finally, to determine whether proteinopathy in primary somatosensory cortex was related to cognitive function in patients on the
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Fig. 5. Amyloid-b uptake in primary somatosensory cortex predicts learning in patients on the AD spectrum. The histogram and density plot on the left indicates the distribution of
amyloid-b SUVRs (x-axis) at the peak voxel of the MEG somatosensory response in patients on the AD spectrum (shown on the inlaid PET image). The scatterplot on the right indicates the relationship between this somatosensory amyloid-b uptake (in SUVRs; x-axis) and learning function (y-axis) in patients on the AD spectrum, above and beyond the effects
of age. The line of best ﬁt is overlaid with 95% conﬁdence intervals indicated in the shaded area, as are the partial correlation coefﬁcient and corresponding p-value.

AD spectrum, we extracted SUVRs from the peak voxel identiﬁed in
the MEG gamma-frequency analysis and regressed these data on
each of the ﬁve cognitive domain scores. We found a signiﬁcant relationship between learning domain scores and amyloid-b SUVRs, such
that increased amyloid-b pathology in primary somatosensory cortex
predicted worse learning performance (partial correlation; r(33) = .47, p = .005; Fig. 5). No such effect was observed for memory (r
(33) = .31, p = .075), verbal function (r(33) = .22, p = .222), processing speed (r(33) = .18, p = .315), or attention (r(33) = .30, p = .086).
Of note, this local proteinopathy did not signiﬁcantly predict the relative amplitude of somatosensory responses (r(33) = .17, p = .339), nor
the functional gating of redundant somatosensory information (r
(33) = .12, p = .494).
4. Discussion
Despite an extensive literature reporting somatosensory dysfunction in animal models of AD [28,29], very little evidence exists supporting such pathology in human patients. While this discrepancy
might be partially attributable to inherent differences in the AD neuropathology of humans and that observed in animal models, we ﬁnd
evidence that it might instead stem from a robust suppression effect
attributable to between-participant variability in cognitive function
in AD, explicitly in two key domains: attention and processing speed.
Initial models of functional differences in gamma-frequency somatosensory processing between patients on the AD spectrum and cognitively-normal older adults showed only weak and marginallysigniﬁcant effects. However, the addition of attention and processing
speed cognitive scores to these models revealed pronounced somatosensory dysfunction in these patients, indicating a suppression effect
that was substantiated using a bootstrapping approach for signiﬁcant
indirect effects. Speciﬁcally, between-participant variability in processing speed abilities masked a substantial increase in the amplitude
of the neural gamma band response to somatosensory stimulation,

while similar variability in both attention and processing speed
masked a considerable increase in the functional gating of redundant
somatosensory information (i.e., hyper-gating) of the same neural
response. These ﬁndings mark one of the ﬁrst studies to report key
differences in somatosensory processing in patients on the AD spectrum, while also providing a theoretical mechanism for the notable
lack of such ﬁndings in extant literature.
The practical implications of these ﬁndings are twofold. First, and
perhaps most importantly, the robust suppression effects that we
report here indicate that the ﬁdelity of neural processing of primary
somatosensory stimuli in patients with AD is dependent on interindividual variabilities in attentional and processing speed. This
dependency should be taken into account in future studies of primary
sensory function more broadly to better understand the nuanced
effects of AD on, for example, visual and auditory processing. This
appears to be particularly important for the study of high-frequency
oscillations, as we found no evidence for suppression of the evoked,
theta, alpha, or beta responses by cognitive variability. Second, this is
one of the ﬁrst reports of pronounced differences in cortical somatosensory processing in people with AD, and to our knowledge, the ﬁrst
report of somatosensory gating deﬁcits in this patient group. These
ﬁndings should guide future studies on the mechanistic bases of this
effect. For example, using a previously reported approach [23] to systematically interrogate the inﬂuence of directed attention on somatosensory gating in these patients would be useful to determine the
inter-regional functional connections that potentially mediate ADrelated changes in somatosensory gating.
Deﬁcits in attention and processing speed are both well documented in patients with AD [13,14], however the degree of such
impairments often vary considerably across individuals, as was the
case in our sample. In contrast, reports of somatosensory dysfunction
in this patient group are exceedingly rare, with the notable exception
of a study that used MEG to examine somatosensory event-related
potentials in patients with mild cognitive impairment and AD [12]. In
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this study, Stephen et al. found a modest but signiﬁcant increase in
somatosensory response amplitude in patients with mild cognitive
impairment, but no somatosensory gating effects were explored.
Interestingly, post-hoc exploration of their data revealed that performance on neuropsychological tests may have had a qualitative suppression effect on this difference, however this possibility was not
tested empirically. Although highly informative, this study did not
restrict the participant sample to biomarker-conﬁrmed patients, and
did not comprehensively evaluate the role of distinct neuropsychological domains to such suppression effects, limiting possible interpretations. Our ﬁndings extend this literature substantially, by
showing that both the relative response amplitude to stimulation
and the functional gating of redundant somatosensory information
are increased in patients on the AD spectrum when cognitive function is considered in parallel. In other words, when cognitive function
is taken into account, patients on the AD spectrum exhibit abnormally stronger somatosensory responses and more robust gating (i.e.,
hyper-gating).
Somatosensory function has been found to be impaired in a number of other neurological, developmental, and psychiatric disorders,
including Parkinson’s disease [58], HIV-associated neurocognitive
disorders [42,59 61], autism [62], cerebral palsy [63, 64], schizophrenia [65], and others. Typically, such deﬁcits are indicated by a
reduced neural response to somatosensory stimuli, however, our
ﬁndings indicate the inverse in AD: a hyper-sensitivity to stimulation.
This aligns with previous studies that used transcranial magnetic
stimulation (TMS) to examine motor cortex excitability in patients
with AD, and found that weaker stimulation was required to elicit a
similar motor-evoked potential, indicating hyper-excitability of the
motor cortex [66,67]. Such motor hyper-excitability has been linked
to impaired high-frequency glutamatergic neurotransmission in local
excitatory intracortical circuits [66,68], and thus it seems likely that
similar mechanisms underlie the high-frequency somatosensory
excitability that we ﬁnd in the current study. Our novel ﬁnding of a
robust pattern of stronger somatosensory gating in patients on the
AD spectrum is in stark contrast to previous reports of reduced auditory gating in AD [8 11]. Interestingly, this decreased gating of
redundant auditory information in AD has been shown to also be
mediated by attention function [10], indicating a bi-directional interplay between cognitive variability and sensory gating in the auditory
and somatosensory domains in AD. Importantly, hyper-gating of
redundant stimuli is not necessarily beneﬁcial, as children with cerebral palsy exhibit a similar phenomenon in high-frequency somatosensory responses [63].

group, and the absence of both for the cognitively-normal controls,
were essential in reducing variability within our participant groups,
substantial variability in clinical and cognitive metrics within the
groups was still quite apparent. Substantiating the effects reported
here in larger participant groups is essential to enhance generalizability. This is particularly important given that AD is a highly heterogeneous disorder, and so examining these effects in a larger patient
sample might also allow for generalization to sub-types of AD, which
are recognized as meaningfully distinct [71 73].
5. Conclusion
In conclusion, the differences in the neural dynamics observed
here indicate that, although masked by highly variable between-participant declines in cognitive function, neural processing in the primary somatosensory cortices is strongly impacted by AD. Further, the
robust suppression effects on such differences by attention and processing speed abilities in these patients indicate that potential cognitive mediators should be better modeled and controlled in the AD
neuroimaging literature.
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